Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Oratz

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Cancer Research|July 15, 1991
Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccineR Oratz, M Dugan, D F Roses, et al.
Journal of the National Cancer Institute|November 18, 1992
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicinH Hochster, L Liebes, S Wadler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1994
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimenH Hochster, L Liebes, J Speyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicityC Wasserheit, A Frazein, R Oratz, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 28, 1998
Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignanciesM A Rosenthal, D Dennis, L Liebes, et al.
Journal of the National Cancer Institute|May 6, 1992
Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanomaL Liebes, C M Walsh, A Chachoua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic studyH Hochster, L Liebes, J Speyer, et al.
Surgery, Gynecology & Obstetrics|April 1, 1991
Survival with regional and distant metastases from cutaneous malignant melanomaD F Roses, N S Karp, R Oratz, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|November 25, 2000
Decrease in circulating tumor cells as an early marker of therapy effectivenessJ C Bystryn, J Albrecht, S R Reynolds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatmentW F Symmans, M D Volm, R L Shapiro, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancer Research|July 15, 1991
Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccineR Oratz, M Dugan, D F Roses, et al.
Journal of the National Cancer Institute|November 18, 1992
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicinH Hochster, L Liebes, S Wadler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1994
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimenH Hochster, L Liebes, J Speyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicityC Wasserheit, A Frazein, R Oratz, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 28, 1998
Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignanciesM A Rosenthal, D Dennis, L Liebes, et al.
Journal of the National Cancer Institute|May 6, 1992
Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanomaL Liebes, C M Walsh, A Chachoua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic studyH Hochster, L Liebes, J Speyer, et al.
Surgery, Gynecology & Obstetrics|April 1, 1991
Survival with regional and distant metastases from cutaneous malignant melanomaD F Roses, N S Karp, R Oratz, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|November 25, 2000
Decrease in circulating tumor cells as an early marker of therapy effectivenessJ C Bystryn, J Albrecht, S R Reynolds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatmentW F Symmans, M D Volm, R L Shapiro, et al.
Pageof 3